(Q44617042)

4 December 2017

title

Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer (English)

1 reference

4 December 2017

1 reference

3

1 reference

4 December 2017

4

1 reference

4 December 2017

5

I F Tannock

1 reference

4 December 2017

Francisco Vera-Badillo

series ordinal

1

object named as

F E Vera-Badillo

1 reference

4 December 2017

R Shapiro

2

1 reference

4 December 2017

publication date

9 January 2013

1 reference

4 December 2017

1 reference

4 December 2017

volume

24

1 reference

4 December 2017

issue

5

1 reference

4 December 2017

page(s)

1238-1244

1 reference

Systematic review of the empirical evidence of study publication bias and outcome reporting bias

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Bias due to changes in specified outcomes during the systematic review process

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Adverse events in randomized trials: neglected, restricted, distorted, and silenced.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Better reporting of harms in randomized trials: an extension of the CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Outcome selection bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Factors associated with failure to publish large randomized trials presented at an oncology meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Why most published research findings are false

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Balancing benefits and harms in health care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Reporting of Safety Results in Published Reports of Randomized Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Limitations are not properly acknowledged in the scientific literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Adjuvant docetaxel for high-risk, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Endpoints for assessing drug activity in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Progression-free survival: meaningful or simply measurable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

When are "positive" clinical trials in oncology truly positive?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS636

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS636

1 reference

4 December 2017

1 reference